2022
DOI: 10.1101/2022.06.09.495553
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

G-Trap Assay II: Characterization of blood Leukocyte Functionality differentiates immune activation and immune suppression in bacteremia patient samples

Abstract: Sepsis is a severe organ dysfunction syndrome caused by a dysregulation of the immune system’s response to infection. Unfortunately, most infection-causing pathogens aren’t routinely detectable in real-time to enable targeted and lifesaving treatment. Thus, clinicians frequently have limited data on which to base treatment decisions. A complete blood count with differential is available within 24 h, and positive culture is only available in ∼30% of cases. Furthermore, a blood culture, the traditional gold stan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 56 publications
(65 reference statements)
0
2
0
Order By: Relevance
“…We have initiated further work targeting the immune-performance status of infected patients' leukocytes to assess the functionality of leukocytes in infected patients and the net effect of empiric antibiotic treatment. [71] MATERIALS AND METHODS Effector Proteins. Glutathione S-transferase (GST) tagged-effector chimeras used for the studies are as follows: p21 activated kinase protein binding domain (PAK-1 PBD), a Rac1 effector, was obtained from Millipore Sigma, Rhotekin-RBD, a Rho effector protein, was purchased from Cytoskeleton (Denver, CO), RalGDS-RBD, a Rap1 effector protein expressed and purified from a plasmid, kindly provided by Dr. Burridge (UNC-Chapel Hill) [72], and GST-RILP was prepared as previously described.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We have initiated further work targeting the immune-performance status of infected patients' leukocytes to assess the functionality of leukocytes in infected patients and the net effect of empiric antibiotic treatment. [71] MATERIALS AND METHODS Effector Proteins. Glutathione S-transferase (GST) tagged-effector chimeras used for the studies are as follows: p21 activated kinase protein binding domain (PAK-1 PBD), a Rac1 effector, was obtained from Millipore Sigma, Rhotekin-RBD, a Rho effector protein, was purchased from Cytoskeleton (Denver, CO), RalGDS-RBD, a Rap1 effector protein expressed and purified from a plasmid, kindly provided by Dr. Burridge (UNC-Chapel Hill) [72], and GST-RILP was prepared as previously described.…”
Section: Discussionmentioning
confidence: 99%
“…We have initiated further work targeting the immune-performance status of infected patients’ leukocytes to assess the functionality of leukocytes in infected patients and the net effect of empiric antibiotic treatment. [71]…”
Section: Discussionmentioning
confidence: 99%